Make or break for costimulatory blockers

Article metrics

  • An Erratum to this article was published on 01 March 2004
  • An Erratum to this article was published on 01 April 2004

Immunomodulator CTLA4-Ig was set to be the miracle drug for organ transplantation a dozen years ago, but then faded from view. Now, with startling results in rheumatoid arthritis, costimulatory blockers are on a comeback. Ken Garber reports.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Structures of the interacting surfaces of complexes of CTLA-4 (cyan) and B7 (purple).
Figure 2: On the block.

References

  1. 1

    Kremer, J.M. et al. N. Engl. J. Med. 349, 1907–1915 (2003).

  2. 2

    Lafferty, K.J. & Cunningham, A.J. Aust. J. Exp. Biol. Med. Sci. 53, 27–42. (1975).

  3. 3

    Martin, P.J. et al. J. Immunol. 136, 3282–3287 (1986).

  4. 4

    Cohen, J. Science 257, 751 (1992).

  5. 5

    Waldholz, M. Wall Street Journal August 7 (1992), p. B8.

  6. 6

    Oliver, S. Forbes 154, 190, (December 19, 1994).

  7. 7

    Davis, S.J. et al. Nat. Immunol. 4, 217–224 (2003).

  8. 8

    Mellor, A.L. & Munn, D.H. Immunol. Today 20, 469–473 (1999).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Garber, K. Make or break for costimulatory blockers. Nat Biotechnol 22, 145–147 (2004) doi:10.1038/nbt0204-145

Download citation

Further reading